Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

Additional investment and resources will accelerate Biocomposites' international expansion and innovation in products for use in infection management HELLERUP, Denmark, LONDON and KEELE ...

Alcohol Justice has released its February 2025 eNews, a comprehensive roundup of the latest news, research, and advocacy ...

As Ramadan approaches, Also Sophia is proud to announce the launch of its latest Ramadan and Eid home decor collection, now ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns (US$800 million) in relation to the drug after adverse clinical trial results.

The Catalent Board also includes Jonathan Levy, Senior Partner at Novo Holdings, and Charles Patten, Partner at Novo Holdings, both of whom joined the Board upon Catalent becoming a private company ...

Novo Nordisk, the Danish pharmaceutical giant, has filed a lawsuit against Singapore-based KBP Biosciences and its founder, Huang Zhenhua, alleging KBP Biosciences misrepresented the effectiveness of ...

Spinnaker Trust raised its holdings in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after buying an ...